Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Laboratory for Molecular Medicine, |
RCV000613702 | SCV000712072 | likely benign | not specified | 2016-05-21 | criteria provided, single submitter | clinical testing | p.Gln4Arg in exon 2 of MYH9: This variant is not expected to have clinical sign ificance because although the glutamine (Gln) at position 4 is conserved in mamm als, it is not conserved in evolutionary distant species, with over 10 species ( birds, reptiles, fish) having an arginine (Arg). It has been identified in 3/85 94 East Asian chromosomes by the Exome Aggregation Consortium (ExAC, http://exac .broadinstitute.org; dbSNP rs773960235). In summary, this information indicates that this variant is likely benign. |
Gene |
RCV001540673 | SCV001758579 | likely benign | not provided | 2021-05-21 | criteria provided, single submitter | clinical testing | |
Invitae | RCV001540673 | SCV002284655 | likely benign | not provided | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Prevention |
RCV004527680 | SCV004104827 | uncertain significance | MYH9-related disorder | 2022-11-30 | criteria provided, single submitter | clinical testing | The MYH9 c.11A>G variant is predicted to result in the amino acid substitution p.Gln4Arg. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.040% of alleles in individuals of East Asian descent in gnomAD (http://gnomad.broadinstitute.org/variant/22-36745271-T-C). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |
Ambry Genetics | RCV004024891 | SCV004943587 | uncertain significance | Inborn genetic diseases | 2023-11-17 | criteria provided, single submitter | clinical testing | The c.11A>G (p.Q4R) alteration is located in exon 2 (coding exon 1) of the MYH9 gene. This alteration results from a A to G substitution at nucleotide position 11, causing the glutamine (Q) at amino acid position 4 to be replaced by an arginine (R). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |